Background: Monitoring disease incidence and transmission patterns is important to characterize groups at risk for hepatitis C virus (HCV) infection. Clinical cases generally represent about 20% to 30% of all newly acquired infections.
T

HE MAIN FOCUS OF CLINICAL
research since the identification of the hepatitis C virus (HCV) 20 years ago has been development of effective medical management and treatment for the estimated 3 to 4 million chronically infected persons nationwide to prevent progression and reduce severity of liver disease. 1 Identifying persons at high risk for HCV infection depends on knowledge of the characteristics of HCV-infected persons; these characteristics are a reflection of the past incidence and transmission patterns of acute HCV infection. [2] [3] [4] Cases of acute disease represent approximately 20% to 30% of all newly acquired infection, and the case-infection ratio does not seem to differ by type of exposure. Collecting information about exposures shortly after onset of illness from persons with acute hepatitis C allows for an examination of possible exposures that may have been the source of infection since the temporal sequence between the exposure and onset of disease is known. Data from the Sentinel Counties (see details in the "Methods" section) have been used to identify risk factors for acquiring infection by comparing the frequency of exposures reported by cases compared with population-based controls. 5, 6 The distribution of risk factors found to be associated with acquiring hepatitis C can then be used to describe cases subsequently identified in the same settings to monitor epidemiological changes. In this analysis, we examined changes in incidence and transmission patterns of acute hepatitis C in the Sentinel Counties during a 25-year period from 1982 to 2006.
METHODS
STUDY POPULATION
In the United States, nationwide surveillance for acute hepatitis C has been conducted by the Centers for Disease Control and Prevention (CDC) since 1982 when it was a diagnosis of exclusion known as non-A, non-B hepatitis. Sensitive laboratory tests to distinguish acute hepatitis A and hepatitis B were just evolving, and incidence estimates for all types were hampered by underreporting and inaccurate diagnosis. To improve ascertainment of acute hepatitis cases by type, including non-A, non-B hepatitis, the CDC implemented in 1982 a program of intensive population-based surveillance for acute viral hepatitis in select counties typical of communities in the United States (detailed methods have been published elsewhere). 5, 7, 8 This Sentinel Counties surveillance project continued through 2006 when it was discontinued owing to low numbers of new cases and lack of resources to expand the number of participating sites.
Patients with acute viral hepatitis were identified from cases reported to 6 US county health departments (total population of approximately 4.5 million persons): Denver City/Denver County, Colorado (1982 Colorado ( -2006 5, 7, 8 Reports were received from physicians, clinics, hospitals, and laboratories and reviewed by a full-time study coordinator at each health department for criteria necessary to meet the case definition. These coordinators encouraged reporting through newsletters, telephone calls, and regular contact with community physicians and infection control practitioners.
CASE DEFINITION AND DATA COLLECTION
We defined acute hepatitis C as (1) the discrete onset of symptoms consistent with acute viral hepatitis, (2) serum aminotransferase levels greater than 2.5 times the upper limit of normal with or without jaundice, (3) IgM antibody to hepatitis A virus negative, (4) IgM antibody to hepatitis B core antigen negative, (5) antibody to HCV (anti-HCV) or HCV RNA positive, and (6) exclusion of other etiologies of liver injury (eg, drug or toxin exposures) as ascertained by interview of the diagnosing physician and review of patient medical records. Particular attention was paid to clinical presentation, history of alcohol use, prescription and nonprescription medications, recent hepatotoxic exposures, and the results of other laboratory testing to exclude other etiologies of liver injury. Serologic specimens were collected from patients within 6 weeks of onset of illness. Patients identified before 1991 met the same clinical case definition with the exception of testing for anti-HCV or HCV RNA because samples from this period were not uniformly available for retrospective testing.
Patients were interviewed by a trained study investigator using a structured questionnaire to obtain clinical, demographic, and epidemiologic data designed to elicit information on both known and potential risk factors for acquiring HCV. Data were also collected on certain behaviors that occurred over the lifetime of the case patient. Beginning in 1990, we expanded our evaluation of potential sources for infection by interviewing and collecting serologic specimens from sexual and household contacts of patients with acute hepatitis C. Beginning in 1991, we collaborated with blood collection facilities to identify and retest the donors of the units of blood received by patients who reported a history of blood transfusion in the 6 months preceding onset of illness. Healthcare-related and dental procedures were evaluated for all patients who denied injection drug use (IDU), occupational exposure to blood, and sexual or household contact with an HCV-positive person. This evaluation included review of available medical records to identify additional incident cases and potential sources of infection (ie, exposure to known HCV-positive health care personnel or patients). Beginning in 1996, patients reporting IDU during their exposure period were asked questions relating to their drug use, including which type of drugs they used and how long they had injected before their illness onset. Beginning in 2001, patients were asked if they had ever been incarcerated or in a substance abuse or drug treatment program to assess the potential for primary prevention services offered to injection drug users in these settings to reduce their risk of HCV infection.
ASSIGNMENT OF RISK FACTORS FOR INFECTION
The exposure period (incubation period) for acute hepatitis C was defined as the 6 weeks to 6 months prior to onset of illness. Based on results of case-control studies of acute disease, 6, 9 patients were considered to have a known risk factor for acquiring hepatitis C if during their exposure periods they reported having had any of the following: (1) blood transfusion, (2) IDU, (3) occupational exposure to blood, (4) chronic hemodialysis, (5) sexual contact with a person known to be anti-HCV positive, or (6) household contact with a person known to be anti-HCV positive. For patients who reported more than 1 known risk factor during the exposure period, a single category was assigned that represented their more likely source of infection based on the relative efficiency of the transmission route according to the order described herein. To address concerns about underreporting of high-risk drug and sexual behaviors, patients who denied any of the 6 known risk factors were shown a list of these same factors at the end of the interview and asked if any one of them applied without having to specify which one. This "aggregate risk category" was incorporated during 1996 to 2006.
Patients who reported no known risk factors for acquiring hepatitis C during their exposure periods were described according to other high-risk sexual and drug practices that might indicate recent exposures not reported during interview. 10 These practices included (1) sexual contact with a person suspected of having hepatitis C during the exposure period, (2) more than 2 heterosexual partners during the exposure period, (3) a lifetime history of IDU, and (4) a lifetime history of ever snorting any illegal drug.
Hepatitis C incidence rates were calculated by using countyspecific US Census Bureau data 11 with intercensal population estimates. Because census data on Hispanic ethnicity were not available at the county level before 1990, county-specific Hispanic population estimates from 1990 were used for prior time periods. For the purposes of analysis, the study period was divided into 3 intervals based on trends in incidence: 1982 to 1989 (8 years), 1990 to 1993 (4 years), and 1994 to 2006 (13 years). Differences in proportions were compared using a 2-tailed Mantel-Haenszel 2 test. PϽ.05 was considered statistically significant. This project was reviewed and received human subjects approval from the institutional review boards of the CDC and each participating county health department.
RESULTS
DISEASE INCIDENCE
A total of 2075 patients with acute hepatitis C were identified over the 25-year period. During 1982 to 1989, the incidence of hepatitis C averaged 7.4 cases per 100 000 population (95% confidence interval [CI], 6.4-8.5 per 100 000) and differed between counties. Incidence was higher than average in 2 of the counties (12.2 per 100 000 with a peak of 16.6 per 100 000 in Denver City/Denver County and 11.1 per 100 000 with a peak of 17. 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 100 000 (95% CI, 0.5-1.0 per 100 000) population and was similar in all counties. The trends in overall incidence for age, sex, and racial/ ethnic groups are presented in Table 1 . During 1982 to 1989, the highest incidence was among persons 20 to 29 years of age followed by those 30 to 39 years of age. During 1990 to 1993, these age groups exhibited the largest declines (approximately 90%), after which the highest incidence was in persons 30 to 39 years of age. Average incidence rates were similar for males and females during the study period, although there was a slight male predominance (male to female ratio, 1.25:1) before 1990. Among the 3 most common racial/ethnic groups, Hispanics had rates of disease approximately 3 times higher than non-Hispanic whites and blacks in all time intervals.
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS
The median age of patients was 31.0 years (range, 1-97 years). Patients were significantly older during the 1994-2006 period compared with the 1982-1989 period (median ages, 36 years and 31 years, respectively) (PϽ.001). Among patients, 53.4% were male, 67.0% were nonHispanic white, 12.5% were non-Hispanic black, and 17.6% were Hispanic ( Table 2 ). There were no significant differences in proportions of patients by sex or race/ ethnicity over the study periods. Most patients (74.1%) had 12 or fewer years of education.
Approximately 92% (91.9%) of patients had alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels 7 or more times the upper limit of normal; 77.3% had jaundice ( (Table 2) .
TRANSMISSION PATTERNS
Of the 2075 patients with acute hepatitis C identified during 1982 to 2006, 1748 (84.2%) were interviewed. Risk factor information from these cases was used to evaluate trends in transmission patterns during the study period. 
Injection Drug Use
Injection drug use was the most commonly reported risk factor in all study intervals. The number of IDU-related cases declined after 1989, consistent with the overall decline in incidence. 
Blood Transfusion
There was a steady decline over the entire study period in both the number and proportion of persons who reported receiving a blood transfusion during the 6 months prior to illness, with the sharpest declines occurring before 1986 and after 1993. Eighteen of 270 patients (6.7%) denied IDU during the exposure period but reported they had previously injected (ie, Ͼ 6 months before illness onset), and 21 of 270 (7.8%) reported ever snorting illegal drugs. Nine patients (3.3%) reported health care occupations that involved potential exposures to blood. Among the 5 patients identified beginning in 1998 when the question was added, 1 patient reported a sharps injury 8 weeks prior to symptom onset, 2 reported other unspecified work-related exposures to blood, and 2 did not report any specific exposures. Four patients (1.5%) reported having nonsexual household contact with an HCV-positive person as their only risk factor. An additional 10 patients (3.7%) reported an unspecified risk factor as listed in the "aggregate risk category."
Cosmetic and alternative medical procedures such as tattooing, body piercing, and acupuncture were uncommonly reported during 1994 to 2006. Of 16 patients (5.9%) who reported receiving a tattoo during the exposure period, 8 (50.0%) also reported current IDU, 1 reported having a household member with HCV, and 2 reported previous but not current IDU. Similarly, of 14 patients (5.1%) reporting piercing and 6 (2.2%) reporting acupuncture dur- b For patients who reported more than 1 known risk factor during the exposure period, a single category was assigned that represented their more likely source of infection (see the "Methods" section).
c But 14.5% who denied IDU during exposure period reported prior injecting (6.7%) or intranasal (7.8%) drug use.
ing the exposure period, 8 (57.1%) and 5 (83.3%), respectively, also reported current IDU.
Male homosexual activity during the exposure period was not common among persons identified as having acute hepatitis C. Of the 21 patients (7.8%) who reported such activity during 1994 to 2006, 12 (57.0%) also reported current (n = 9) or past (n = 3) IDU. Among the remaining 9 patients, 6 reported having 2 or more male partners in the 6 months prior to their illness. Among the 3 patients with a single male partner, 1 reported that the partner had hepatitis C, and 1 reported that his partner had a history of hepatitis.
COMMENT
We report findings of 25 years of continuous, highquality, population-based surveillance for acute symptomatic hepatitis C in the United States, including dramatic changes in the epidemiologic characteristics of acute hepatitis C. The incidence, which peaked in the 1980s, declined by more than 90% after 1989 and subsequently remained low and remarkably stable. While this decline was observed across all demographic groups, it was most striking in younger adults 20 to 29 years old and those 30 to 39 years old and in the number of patients who reported IDU. Despite this decline, IDU accounted for an increasing proportion of acute hepatitis C during the study period. In contrast, the largest decline in the number of acute cases attributed to blood transfusion occurred before 1989 and was temporally related to changes in donor screening practices to prevent human immunodeficiency virus transmission. 12 The decline in both number and proportion of transfusionassociated cases continued as donors were tested with surrogate and successive generations of HCV assays and following the introduction of a screening assay for anti-HCV in 1992. In the latter years of the study, the number of transfusion-associated cases, if any, was very small, particularly after 1998 when testing for HCV RNA became routine.
The reasons for the decline in the number of IDUrelated acute hepatitis C cases are not as clear, but a similar trend was observed for acute hepatitis B.
8 Several factors may have played a role, including the saturation of the IDU community with HCV infection (overall prevalence, Ͼ80%) 13, 14 and harm reduction education and programs. Although the incidence of hepatitis C among seronegative injection drug users remains high, they account for a small proportion relative to the population previously infected. [15] [16] [17] [18] In our study, approximately 14% of infections potentially could be attributed to sexual transmission; these patients, who reported no other risk factors, had sex with an infected or suspected-to-be infected partner or had more than 2 partners during their exposure period. Casecontrol studies of persons with acute hepatitis C identified similar risk factors as significantly associated with acquiring disease. 6, 9 However, long-term partners of infected patients have a low prevalence of infection, similar to that of the general population. 2, 19 Although factors that might facilitate HCV transmission between sexual partners are not known, persons with acute HCV infection may be more infectious than those with chronic infection. 20 About a third of patients ascertained during the most recent surveillance period reported no recognized risk factor during their exposure period. However, most of these patients reported illicit drug use behaviors at some time in the past, suggesting the possibility that current IDU was not reported during the interview. Other studies have shown that IDU is underreported by some persons, including volunteer blood donors. [21] [22] [23] [24] Cosmetic procedures, such as tattooing and body piercing, were uncommonly reported, and previous case-control studies did not find associations between acquiring disease and having these procedures during the incubation period. 6, 9 In addition, HCV prevalence is low among persons who have a history of tattooing or body piercing but deny IDU. 25, 26 While all percutaneous procedures are a potential source for blood-borne infections and should be performed using aseptic technique, routine testing based on histories of cosmetic procedures alone is not warranted.
Investigations of patients in the Sentinel Counties who reported no known risk factors did not find any evidence of iatrogenic transmission. Previous case-control studies did not find associations between acquiring disease and medical, surgical, and dental procedures. 6, 9 Percutaneous procedures are also a source of HCV transmission in health care settings, and an increasing number of outbreaks have been recently reported. 27 Most of these were due to unsafe injection practices or other iatrogenic exposures in outpatient settings. Prevention efforts need to be directed toward ensuring that aseptic techniques are used for preparing and administering therapeutic injectable medications in any setting.
This surveillance system had several limitations. Only patients with symptoms of acute viral hepatitis, which represent a minority of all HCV infections, were included. Hence, the incidence of new HCV infections cannot be directly calculated from these data. Nonetheless, the specific case definition, used consistently over time, allows for monitoring of trends. Furthermore, because route of exposure or the size of inoculum does not seem to affect the likelihood of having symptoms, these cases should represent the broad range of risk settings. There is the potential for ascertainment bias owing to differential reporting by source of infection (eg, a health care worker with hepatitis C may be more likely to be reported than those with drug or sexual risk factors). 28 However, findings from our surveillance study are generally consistent with the characteristics of the current population-based cohort of persons chronically infected with HCV. 1, 29 The overall prevalence in the general population did not change during the past decade as predicted by the low and stable incidence observed during that time. Most chronically infected persons were 40 to 59 years old, a cohort effect resulting from high incidence rates when they were younger, and 40% to 50% reported ever injecting drugs while less than 10% reported receiving a blood transfusion. Our study relied on self-reporting of such risk factors as IDU, which may have resulted in an underestimation of these factors. The use of injection drugs is a socially stigmatized illegal activity that may have resulted in people being unwilling to admit this behavior.
